Literature DB >> 3694681

A low concentration of nisoldipine reduces ischemic heart injury: enhanced reflow and recovery of contractile function without energy preservation during ischemia.

J A Watts1, J P Whipple, A A Hatley.   

Abstract

Isolated working rat hearts which received no drug treatment had reduced ATP and creatine phosphate levels and increased lactate content during 20 min of ischemia. When subjected to 33 min of ischemia and 30 min of reperfusion, these hearts recovered low values of cardiac output (9.8 ml/min), heart rate, maximum developed pressure, pressure-rate product (72.9, 32.6, 27.5% of control, respectively), had low levels of tissue ATP, and reduced coronary flow upon reperfusion. Addition of nisoldipine (1 nM) 10 min before ischemia caused no decrease in cardiac output or heart rate, slightly decreased maximum developed pressure and pressure-rate product (93% of control), and did not reduce the degradation of ATP and creatine phosphate or the accumulation of lactate during 20 min of ischemia. When nisoldipine was included 10 min before ischemia, during ischemia (33 min) and reperfusion (30 min), however, the recovery of cardiac function and tissue ATP levels was significantly increased. This protective effect occurred when drug treated ischemic hearts were reperfused with control buffer, indicating residual effects. The beneficial effects of nisoldipine were not due to changes in afterload or preload (isolated perfused heart), collateral flow (zero flow model), energy preservation during ischemia (little contractile depression, ATP not enhanced during ischemia), or reduced lactate accumulation during ischemia. The beneficial effects were associated with increased coronary flow (31% higher than no drug) during reperfusion, indicating a reduction in the no-reflow phenomenon.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3694681     DOI: 10.1016/s0022-2828(87)80391-7

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

1.  Adenosine-induced increase in myocardial ATP: are there beneficial effects for the ischaemic myocardium?

Authors:  T Hohlfeld; D J Hearse; D M Yellon; W Isselhard
Journal:  Basic Res Cardiol       Date:  1989 Sep-Oct       Impact factor: 17.165

Review 2.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  H A Friedel; E M Sorkin
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

3.  Stereoisomers of BAY K 8644 show opposite activities in the normal and ischaemic rat heart. A comparison with nifedipine.

Authors:  F T van Amsterdam; N C Punt; M Haas; M S van Amsterdam-Magnoni; J Zaagsma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

4.  Protection by verapamil and nifedipine against ischaemia-induced loss of [3H]-(+)-PN 200-110 binding sites in the rat heart.

Authors:  F T van Amsterdam; M S van Amsterdam-Magnoni; M Haas; N C Punt; J Zaagsma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990 Jan-Feb       Impact factor: 3.000

5.  Intracellular calcium and ventricular function. Effects of nisoldipine on global ischemia in the isovolumic, coronary-perfused heart.

Authors:  I Amende; L A Bentivegna; A J Zeind; P Wenzlaff; W Grossman; J P Morgan
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

6.  The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs.

Authors:  G J Grover; S Dzwonczyk; C S Parham; P G Sleph
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

7.  Improvement of ischemic myocardial dysfunction by nisoldipine.

Authors:  K Saida; M Umeda; A Itakura
Journal:  Cardiovasc Drugs Ther       Date:  1994-05       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.